BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 30315258)

  • 41. Daxx Functions Are p53-Independent
    Wasylishen AR; Estrella JS; Pant V; Chau GP; Lozano G
    Mol Cancer Res; 2018 Oct; 16(10):1523-1529. PubMed ID: 29903771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo.
    Wasylishen AR; Sun C; Moyer SM; Qi Y; Chau GP; Aryal NK; McAllister F; Kim MP; Barton MC; Estrella JS; Su X; Lozano G
    Sci Adv; 2020 Aug; 6(32):eaba8415. PubMed ID: 32821827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.
    Chou WC; Lin PH; Yeh YC; Shyr YM; Fang WL; Wang SE; Liu CY; Chang PM; Chen MH; Hung YP; Li CP; Chao Y; Chen MH
    Int J Biol Sci; 2016; 12(12):1523-1532. PubMed ID: 27994516
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunohistochemically Detected Expression of ATRX, TSC2, and PTEN Predicts Clinical Outcomes in Patients With Grade 1 and 2 Pancreatic Neuroendocrine Tumors.
    Uemura J; Okano K; Oshima M; Suto H; Ando Y; Kumamoto K; Kadota K; Ichihara S; Kokudo Y; Maeba T; Nanno Y; Toyama H; Takada Y; Shimada M; Hanazaki K; Masaki T; Suzuki Y
    Ann Surg; 2021 Dec; 274(6):e949-e956. PubMed ID: 31599805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
    de Wilde RF; Edil BH; Hruban RH; Maitra A
    Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
    Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
    Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.
    Werle SD; Ikonomi N; Lausser L; Kestler AMTU; Weidner FM; Schwab JD; Maier J; Buchholz M; Gress TM; Kestler AMR; Kestler HA
    NPJ Syst Biol Appl; 2023 Jun; 9(1):22. PubMed ID: 37270586
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
    Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
    Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase.
    Feng Z; Wang L; Sun Y; Jiang Z; Domsic J; An C; Xing B; Tian J; Liu X; Metz DC; Yang X; Marmorstein R; Ma X; Hua X
    Cancer Res; 2017 Jan; 77(2):401-411. PubMed ID: 27872097
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.
    Simon T; Riemer P; Jarosch A; Detjen K; Di Domenico A; Bormann F; Menne A; Khouja S; Monjé N; Childs LH; Lenze D; Leser U; Rossner F; Morkel M; Blüthgen N; Pavel M; Horst D; Capper D; Marinoni I; Perren A; Mamlouk S; Sers C
    Genome Med; 2022 Mar; 14(1):24. PubMed ID: 35227293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain-associated protein in neuroendocrine tumors.
    Chen SF; Kasajima A; Yazdani S; Chan MS; Wang L; He YY; Gao HW; Sasano H
    Hum Pathol; 2013 Oct; 44(10):2199-203. PubMed ID: 23954140
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.
    Casar-Borota O; Botling J; Granberg D; Stigare J; Wikström J; Boldt HB; Kristensen BW; Pontén F; Trouillas J
    Am J Surg Pathol; 2017 Sep; 41(9):1238-1246. PubMed ID: 28719461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?
    Marinoni I
    Gut; 2022 May; 71(5):847-848. PubMed ID: 33975869
    [No Abstract]   [Full Text] [Related]  

  • 54. Five Novel Genes Related to the Pathogenesis and Progression of Pancreatic Neuroendocrine Tumors by Bioinformatics Analysis With RT-qPCR Verification.
    Xiao Y; Yang Y; Wang Y; Li X; Wang W
    Front Neurosci; 2019; 13():937. PubMed ID: 31607839
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The genetics of neuroendocrine tumors.
    Öberg K
    Semin Oncol; 2013 Feb; 40(1):37-44. PubMed ID: 23391111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical features of ATRX or DAXX mutated neuroblastoma.
    Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
    J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.
    Ziv E; Rice SL; Filtes J; Yarmohammadi H; Boas FE; Erinjeri JP; Petre EN; Brody LA; Brown KT; Covey AM; Getrajdman GI; Maybody M; Raj N; Sofocleous CT; Solomon SB; Reidy-Lagunes D
    J Vasc Interv Radiol; 2018 Nov; 29(11):1519-1526. PubMed ID: 30342802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ATRX-DAXX Complex Expression Levels and Telomere Length in Normal Young and Elder Autopsy Human Brains.
    Cavalcante SG; Silva CPN; Sola PR; Tanaka LY; Oba-Shinjo SM; Marie SKN
    DNA Cell Biol; 2019 Sep; 38(9):955-961. PubMed ID: 31361513
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
    Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
    Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium.
    Mafficini A; Scarpa A
    J Endocrinol; 2018 Mar; 236(3):R161-R167. PubMed ID: 29321190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.